{"id":"NCT03967054","sponsor":"Brian Foy","briefTitle":"Repeat Ivermectin Mass Drug Administrations for MALaria Control II","officialTitle":"Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II): a Double-blind, Cluster-randomized Control Trial for Integrated Control of Malaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-13","primaryCompletion":"2020-11-08","completion":"2024-08-01","firstPosted":"2019-05-30","resultsPosted":"2024-01-11","lastUpdate":"2025-04-10"},"enrollment":4124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Malaria"],"interventions":[{"type":"DRUG","name":"Ivermectin","otherNames":["Iver P"]},{"type":"DRUG","name":"Placebo oral tablet","otherNames":[]}],"arms":[{"label":"Ivermectin mass drug administration","type":"EXPERIMENTAL"},{"label":"Placebo mass administration","type":"PLACEBO_COMPARATOR"}],"summary":"RIMDAMAL II is a double-blind, cluster randomized trial in Burkina Faso designed to test whether repeated ivermectin mass drug administrations, integrated into a monthly delivery platform with standard malaria control measures of seasonal malaria chemoprevention and insecticide-treated bed net distribution in the Sahel, will reduce childhood malaria incidence.","primaryOutcome":{"measure":"Malaria Incidence","timeFrame":"up to 8 months","effectByArm":[{"arm":"Ivermectin Mass Drug Administration","deltaMin":0.0176,"sd":null},{"arm":"Placebo Mass Administration","deltaMin":0.0183,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Burkina Faso"]},"refs":{"pmids":["39919778","36939832"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":2191},"commonTop":["malaria","upper respiratory infection","pruritis","fever","rash"]}}